Prophylaxis News and Research

RSS

Lethal risks associated with preparing dog meat

Eating dog meat is common in many Asian countries, but research conducted as part of the South East Asian Infectious Diseases Clinical Research Network has discovered a potentially lethal risk associated with preparing dog meat: rabies.

16 Mar 2009

Genes more important in cleft lip and palate than previously thought

Comparing 500,000 snippets of human DNA put scientists from the University of Bonn on the right track.

8 Mar 2009

European Commission and US FDA approve intravenous formulation of temozolomide

Schering-Plough Corporation (NYSE:SGP) today announced that the European Commission and the US FDA both approved the intravenous (IV) formulation of temozolomide as an alternative to the already approved oral form of the drug.

5 Mar 2009

Hair helps predicts HIV antiretroviral treatment success

UCSF researchers have found that examining levels of antiretroviral drugs in hair samples taken from HIV patients on therapy strongly predicts treatment success.

3 Mar 2009

Influenza A's resistance to drug Tamiflu increasing

Influenza A viruses (H1N1 subtype) that are resistant to the drug oseltamivir circulated widely in the U.S. during the 2007-2008 influenza season, with an even higher prevalence of drug resistance during the current 2008-2009 influenza season, according to a study to be published in the March 11 issue of JAMA, the Journal of the American Medical Association.

2 Mar 2009

A new monkey model for HIV

By altering just one gene in HIV-1, scientists have succeeded in infecting pig-tailed macaque monkeys with a human version of the virus that has until now been impossible to study directly in animals.

2 Mar 2009

Liver transplant recipients with hepatitis B may need lifelong antiviral treatment

Patients who undergo liver transplantation for hepatitis B-related liver damage should receive lifelong antiviral treatment to keep the disease from coming back.

26 Feb 2009

Blood clots after hip and knee replacements

As the number of hip and knee replacements skyrocket into the coming years, patients and orthopaedic surgeons need to work together to evaluate and assess a potentially fatal complication - blood clots.

26 Feb 2009

ViroPharma reports results of trial for Maribavir in bone marrow transplant patients

ViroPharma Incorporated has announced that its Phase 3 trial evaluating maribavir used as prophylaxis in allogeneic stem cell, or bone marrow, transplant (SCT) patients did not achieve its primary endpoint.

10 Feb 2009

FDA grants priority review of Cinryze C1 inhibitor as treatment for acute attacks of hereditary angioedema

ViroPharma Incorporated has announced that the U.S. Food and Drug Administration (FDA) has granted priority review for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of Hereditary Angioedema (HAE).

5 Feb 2009

Prolonged nevirapine in breast-fed babies prevents HIV infection but leads to drug-resistant HIV

Babies born to HIV-positive mothers and given the antiretroviral drug nevirapine through the first six weeks of life to prevent infection via breast-feeding are at high risk for developing drug-resistant HIV if they get infected anyway, a team of researchers report.

5 Jan 2009

GlaxoSmithKline ready to supply Biota's Relenza to meet CDC recommendations

GlaxoSmithKline (GSK) is prepared to respond to public health needs for Relenza (zanamivir) Inhalation Powder this flu season following a Health Alert Advisory issued by the Centers for Disease Control and Prevention (CDC).

21 Dec 2008

New approaches to prevent blood clots

The largest study ever to examine the preventive use of blood-thinning medication to help prevent deadly blood clots in patients with cancer undergoing chemotherapy presented December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

ViroPharma Inc. submits sBLA for Cinryze to treat acute attacks of hereditary angioedema

ViroPharma Inc. has announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Cinryze C1 Inhibitor (human) as a treatment for acute attacks of hereditary angioedema (HAE).

1 Dec 2008

MedImmune starts phase 1/2a clinical trial for respiratory syncytial virus vaccine

MedImmune today announced that it has initiated a Phase 1/2a clinical trial of a live, attenuated intranasal vaccine in healthy children one month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most common respiratory infection in infants and can cause disease in otherwise healthy infants and children.

3 Nov 2008

Trial demonstrates safety and efficacy of neurally acting anti-migraine agent for treatment of acute migraine

CoLucid Pharmaceuticals, Inc., an innovative biotechnology company focusing on therapies for central nervous system disorders, announced Phase II results of its lead compound COL-144 in the treatment of acute migraine. Results demonstrated that COL-144 was safe and effective in relieving migraine headaches.

7 Sep 2008

Maternal deaths following cesarean delivery can be reduced

Maternal death rates have remained constant in the United States for many decades. Are there any improvements in health care that could reduce these rates further?

4 Aug 2008

Study examines heparin use following cardioembolic stroke

The common practice of administering heparin soon after cardioembolic stroke is associated with an increased risk for serious bleeding, according to an article posted online today that will appear in the September 2008 print issue of Archives of Neurology. However, it appears that anticoagulation with warfarin therapy may safely begin shortly after stroke.

14 Jul 2008

Researchers to compare common ARV as a pill and vaginal gel in unique HIV prevention study

In battle with an epidemic that has outpaced nearly all efforts to contain it, researchers are turning to strategies centered on the same antiretroviral (ARV) drugs that have been used successfully to treat HIV in hopes they will be as effective a stronghold for preventing the virus.

9 Jul 2008

6 in every 100 patients die in hospital due to adverse drug reaction

Six of every 100 patients who die in hospital do so as a consequence of an adverse drug reaction or, in other words, a fatal reaction to medicines. Those are the conclusions of a research carried out at the Department of Medicine of the University of Granada, in collaboration with the Clinical Hospital San Cecilio of Granada, by Alfredo Jose Pardo Cabello and directed by Professors Emilio Puche Canas (Department of Pharmacology) and Francisco Javier Gomez Jimenez (Department of Medicine).

6 Jul 2008